Concepedia
Statistics
Publications
12
Citations
2.2K
H-Index
Active since
2001
Affiliations
Princess Margaret Cancer Centre(Current)
Ontario Institute for Cancer Research
University of Toronto
Cancer Institute (WIA)
Molecular Oncology (United States)
Diana C. Birle is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and pharmacology.
Publications per year
2001–2012
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell, Jordi Rodón, Howard A. Burris et al. · Journal of Clinical Oncology · 2011 · 686 citations · Full text
Medicine, Oncology, Pharmacology +14
The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling
Thierry Virolle, Eileen D. Adamson, Véronique Baron et al. · Nature Cell Biology · 2001 · 394 citations
Life Sciences, Cell Biology, Molecular Biology +14
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Ignacio Durán, Jeremy Kortmansky, Deepti Singh et al. · British Journal of Cancer · 2006 · 317 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +15
Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts
Licun Wu, Diana C. Birle, Ian F. Tannock · Cancer Research · 2005 · 166 citations · Full text
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman, Josep Tabernero, Ian E. Krop et al. · Annals of Oncology · 2012 · 148 citations
Medicine, Oncology, Pharmacology +15
1–5 of 12